Anti-PD-1 Therapy in Advanced Pediatric Malignancies in Nationwide Study: Good Outcome in Skin Melanoma and Hodgkin Lymphoma.
Agata MarjańskaKatarzyna Pawinska-WasikowskaAleksandra WieczorekMonika DrogosiewiczBożenna Dembowska-BagińskaKatarzyna BobeffWojciech MlynarskiKatarzyna Adamczewska-WawrzynowiczJacek WachowiakMałgorzata Anna KrawczykNinela Irga-JaworskaJadwiga Weclawek-TompolKrzyzstof KalwakMałgorzata Sawicka-ŻukowskaMaryna Krawczuk-RybakAnna RaciborskaAgnieszka Mizia-MalarzAgata Sobocińska-MirskaPaweł ŁagunaWalentyna BalwierzJan StyczyńskiPublished in: Cancers (2024)
= 0.002). The best progression-free survival value (0.78) was observed in the group with malignant melanoma. Significantly better effects of immunotherapy were confirmed in patients ≥ 14 years of age and good overall performance ECOG status. Severe adverse events were observed in 30.9% (13/42) patients.